HAVCR2 and precursor B-cell acute lymphoblastic leukemia: Patients with relapsed/refractory disease showed the significant downregulation of TIM-3 expression compared to non-malignant healthy controls, while those with newly diagnosed or remission status did not show significant differences, which indicates that the lower TIM-3 expression may be linked to more aggressive or treatment-resistant forms of B-ALL disease.